Valuation: Compugen Ltd.

Market Cap 272M 233M 218M 199M 376M 25.92B 380M 2.57B 1B 13.08B 1.02B 999M 43.3B P/E 2026 *
-10.3x
P/E 2027 * -10.4x
Enterprise Value 272M 233M 218M 199M 376M 25.92B 380M 2.57B 1B 13.08B 1.02B 999M 43.3B EV / Sales 2026 *
29.4x
EV / Sales 2027 * 35.1x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
1 day+2.26%
1 week+19.88%
Current month+24.47%
1 month+22.90%
3 months+10.38%
6 months+63.41%
Current year+91.18%
1 week 2.47
Extreme 2.47
2.92
1 month 2.17
Extreme 2.17
2.92
Current year 1.51
Extreme 1.51
3.24
1 year 1.3
Extreme 1.295
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 22/09/2025
Director of Finance/CFO 42 14/08/2024
Chief Operating Officer 49 31/12/2023
Director TitleAgeSince
Chairman 59 22/09/2025
Director/Board Member 59 10/06/2018
Director/Board Member 70 10/06/2018
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Free

Chief Operating Officer

70,000 0.0740%
29/07/26 Free

Chairman

100,000 0.1058%
29/07/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%+19.88%+101.72%+152.16% 272M
-0.96%+1.55%+1.73%+23.70% 51.65B
+1.45%-1.73%+465.90%+553.87% 45.31B
+0.62%+4.50%+38.74%+17.45% 42.7B
-0.52%-0.89%+20.91%+84.81% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
+0.18%+1.00%+30.91%+134.80% 17.14B
-0.55%-3.29% - - 16.61B
-1.27%+3.51%+11.60%+29.13% 15.01B
-0.14%+2.58%+81.72%+49.68% 14.21B
Average -0.12%+3.70%+85.27%+121.90% 27.86B
Weighted average by Cap. -0.29%+2.75%+99.66%+136.98%

Financials

2026 *2027 *
Net sales 9.24M 7.92M 7.42M 6.78M 12.79M 881M 12.91M 87.5M 34.06M 444M 34.69M 33.93M 1.47B 7.75M 6.64M 6.22M 5.68M 10.73M 739M 10.83M 73.4M 28.57M 373M 29.1M 28.47M 1.23B
Net income -26.46M -22.68M -21.25M -19.41M -36.63M -2.52B -36.99M -251M -97.58M -1.27B -99.37M -97.21M -4.22B -26.95M -23.09M -21.64M -19.77M -37.3M -2.57B -37.67M -255M -99.37M -1.3B -101M -98.99M -4.29B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
26/08/26 US$2.925 +1.92% 217,506
25/08/26 US$2.870 +10.81% 799,789
24/08/26 US$2.590 -0.96% 218,360
21/08/26 US$2.615 -1.32% 447,161
20/08/26 US$2.650 +8.61% 993,918
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.870USD
Average target price
4.600USD
Spread / Average Target
+60.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGEN Stock